Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL4689065 | 0.90 | RAD52 (0.41) | RAD52LMNARECQLPTGIRALDH1A1 | |
| SCHEMBL2279405 | 0.80 | — | — | |
| Sulfuric Acid SCHEMBL7937538 | 0.72 | ADRA2A (0.35) | RAD52LMNAALDH1A1TSHRADRA2A | |
| SCHEMBL12556606 | 0.66 | — | — | |
| SCHEMBL560406 | 0.66 | — | — | |
| SCHEMBL18546617 | 0.64 | ALDH1A1 (0.33) | RAD52PTGIRALDH1A1 | |
| Sulfuric Acid SCHEMBL15348814 | 0.64 | RAD52 (0.41) | RAD52LMNAALDH1A1TSHRADRA2A | |
| SCHEMBL1586471 | 0.63 | — | — | |
| Sulfuric Acid SCHEMBL6657 | 0.60 | — | — | |
| Sulfuric Acid SCHEMBL7805862 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0887346-B1 | N-Phenyl-alkylsulfonamide derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1315714-B1 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | EP | disclosed |
| EP-1315714-A2 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-6559153-B2 | 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders | SYNTEX (U.S.A.) LLC | 2003-05-06 | — | — | US | disclosed |
| US-20020045614-A1 | Quinazoline derivatives as alpha-1 adrenergic antagonists | SYNTEX (U.S.A.) LLC | 2002-04-18 | — | — | US | disclosed |
| WO-2002018348-A2 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
| US-4436913-A | HYPOTENSIVE AGENTS | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1984-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045614-A1 | Quinazoline derivatives as alpha-1 adrenergic antagonists | ADRB1, ADRA1B, ADRA1D | RAD52 3938/4885LMNA 1059/4885RECQL 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.